Association of GDNF and CNTNAP2 gene variants with gambling

ARUNDHUTI DAS^{1,2,3}, LUCA PAGLIAROLI¹, ANDREA VERECZKEI¹, ESZTER KOTYUK⁴, BANRIDA LANGSTIEH⁵, ZSOLT DEMETROVICS⁴ and CSABA BARTA¹*

¹Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary

²Department of Anthropology, Utkal University, Bhubaneswar, India

³Indian Council of Medical Research, Regional Medical Research Center, Bhubaneswar, India

⁴MTA-ELTE Lendület Adaptation Research Group, Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary

⁵Department of Anthropology, North Eastern Hill University, Shillong, India

(Received: April 20, 2019; revised manuscript received: July 2, 2019; accepted: July 13, 2019)

Background and aims: Some form of gambling can be observed in nearly every society, as the gratification felt upon winning in uncertain conditions is universal. A culturally distinct form of gambling, associated with a traditional sporting event of archery known as "teer," is innate to the province of Meghalaya, India. The objective of this study was to find genetic variants underlying this unique form of behavioral addiction. To better understand game-based gambling, we studied genetic variants related to dopaminergic pathways and other genes previously linked to various psychological disorders. *Methods:* This study was carried out on a sample of 196 Indo-Aryan adults from Shillong, Meghalaya. Genotyping of glial cell line-derived neurotrophic factor (GDNF) polymorphisms was carried out using real-time PCR. We further investigated 32 single nucleotide polymorphisms located in the 3' UTR of additional genes of interest using an OpenArray® real-time PCR platform. *Results:* Case—control analysis revealed a significant association between GDNF variant rs2973033 (p = .00864, $\chi^2 = 13.132$, df = 2) and contactin-associated protein-like 2 (CNTNAP2) variant rs2530311 (p = .0448, $\chi^2 = 13.132$, df = 2) with gambling. *Discussion and conclusions:* Association of the GDNF gene with gambling could be attributed to its involvement in the development and survival of dopaminergic neurons. Our result is in good agreement with previous data indicating the role of GDNF in certain substance addictions. Several rare variants in the CNTNAP2 gene were also implicated in alcohol addiction behaviors.

Keywords: addiction, gambling, genetic, GDNF, CNTNAP2

INTRODUCTION

Substance-related and addictive disorders are conditions characterized using different classes of drugs that produce reward when used in excess, as defined by the fifth edition of *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5; American Psychiatric Association, 2013). Gamebased gambling is considered a prototypical example of behavioral (non-substance) addiction (Robbins & Clark, 2015) in the DSM-5. It is known that about 70%–90% of people gamble at some time in their lives (Shaffer, Hall, & Vander Bilt, 1999; Welte, Barnes, Tidwell, Hoffman, & Wieczorek, 2015); however, only a small portion (1%–2%) will develop a gambling disorder (Xuan et al., 2017).

Gambling involves wagering money or other valuable objects on an event where the outcome is not certain. Thus, gambling implies the willingness to risk something valuable with the hope of a reward. Excessive gambling, however, can lead to negative consequences in subjective well-being by affecting several aspects of daily life, such as mental state, behavior, economy, and relationships. Symptoms are very similar to those observed in substance use dependence (Grant, Potenza, Weinstein, & Gorelick, 2010).

This study was conducted on participants practicing a distinct form of gambling related to the game of archery. In the region of Meghalaya, India, archery (called "teer") is a traditional game among the Khasi population. This sport has been legalized by the local government of Meghalaya and takes place twice a day in the capital city of Shillong. Within a designated arena, a group of professional archers aim and shoot hundreds of arrows at a target. Spectators bid on the last two digits (between 00 and 99) of the total number of arrows that will hit the target. Government-registered counters are spread across the city, and it is here that gamblers buy their tickets with the preferred two-digit number. Following the tournament, individuals who had bid the right guess may collect their prize money from the counters. Despite being a traditional Khasi sport, "teer" has gained so much popularity recently that other communities of Shillong also take part in this particular form of game-based gamble.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated. (SID_1)

^{*} Corresponding author: Csaba Barta, MD, PhD; Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, 37-47 Tuzolto Street, Budapest, 1094, PO Box 260, Hungary; Phone: +36 1 459 1500 ext. 60137; Fax: +36 1 266 7480; E-mail: barta.csaba@med.semmelweis-univ.hu

Therefore, this pilot study was performed on a unique, culturally distinct phenotype, where even collection of the sample was a great challenge and as such it should be considered as an exploratory analysis.

Genetic studies of gambling behavior are sparse in literature (Gyollai et al., 2014). In this study conducted on the Indo-Aryan population from Shillong, we mainly focused on glial cell line-derived neurotrophic factor (GDNF), a gene involved in dopaminergic neuronal development, which has previously been found to be associated with methamphetamine (Yoshimura et al., 2011) and tobacco addiction (Kotyuk et al., 2016). In order to investigate the possible role of epigenetic regulation of gene expression in gambling, different single nucleotide polymorphisms (SNPs) located in 3' untranslated regions (3' UTRs) of additional candidate genes associated with gambling, such as catechol-O-methyltransferase (Grant, Potenza, Weinstein, & Gorelick, 2015; Guillot, Fanning, Liang, & Berman, 2015; Verdejo-Garcia et al., 2013), DRD2 (Fagundo et al., 2014; Hillemacher et al., 2016; Joutsa et al., 2014), GDNF (Kotyuk et al., 2016; Ron & Janak, 2005), monoamine oxidase A (Ibanez et al., 2000), and solute carrier family 6 member 3 (Fagundo et al., 2014; Kordi-Tamandani, Tajoddini, & Salimi, 2015; Stolf et al., 2014). Some other genes earlier shown to be associated with either addiction, such as HTR2A (Cao et al., 2014; Perez-Rubio et al., 2017), CNR1 (Clarke et al., 2013; Icick et al., 2015), contactinassociated protein-like 2 (CNTNAP2; Song & Zhang, 2014) and TNF (Heberlein et al., 2014), or with other psychiatric conditions, such as AADAC (Bertelsen et al., 2016), ACP1 (Willour et al., 2012), IL1RN (Kapelski et al., 2016), IMMP2L (Petek et al., 2001), LHX6 (Paschou et al., 2012), MEIS1 (Hammerschlag et al., 2017), MIR302A (Beveridge, Gardiner, Carroll, Tooney, & Cairns, 2010), NTN4 (Paschou et al., 2014), and SLITRK1 (Abelson et al., 2005; Speed et al., 2008) were also included. It has been shown that microRNAs (miRNAs) regulate multiple signaling cascades implicated in several types of addictive disorders (Bali & Kenny, 2013; Sim et al., 2017; Smith & Kenny, 2017). Since the 3' UTR of a gene serves for binding of various miRNAs, a polymorphism in these sequences might alter the binding affinity of regulatory miRNAs to their target messenger RNAs, therefore influencing the expression of the given gene.

We hypothesized that variants potentially affecting miRNA-directed regulation of gene expression may serve as risk factors for behavioral addictions, such as gambling.

MATERIALS AND METHODS

Participants

Samples were collected from individuals residing in Shillong, Meghalaya, located in the North Eastern region of India. The study includes only those individuals whose pedigree can be traced back for three or more consecutive generations. Thus, 196 unrelated adults (130 males, 66 females, mean age: 27.56 ± 9.139 years) from the Indo-Aryan linguistic group were included in the study. Out of the total sample of 196 individuals, 96 were gamblers (49%) and 100 were non-gamblers (51%) and hence were considered as negative control.

Phenotype measures

The gambling phenotype was determined using the Problem Gambling Severity Index (PGSI). The PGSI classifies the gamblers in four categories: non-problem gambler, low-risk gambler, moderate-risk gambler, and problem gambler. The PGSI was submitted to the participants of the study; the answers were recorded and the gamblers were grouped according to the PGSI parameters. In this study, 5.4% were non-problem gamblers, 12% were low-risk gamblers, 39.1% were moderate-risk gamblers, and 43.5% were problem gamblers. The following parameters were assessed: frequency of gambling, amount of money gambled (from 25 to 15,000 Indian Rupees a day), attitude of the participants, etc. For the statistical analysis in this study, participants were grouped into two categories: gamblers and non-gamblers. The non-gamblers, representing the negative control group, reported no lifetime gambling history.

The SNP selection criteria

SNPs with a minor allele frequency (MAF) greater than 0.05 were selected from the Single Nucleotide Polymorphism Database (http://www.ncbi.nlm.nih.gov/SNP) of the National Centre for Biotechnology Information. The pairwise tagging method using the linkage disequilibrium r2 threshold of 0.8 by the HaploView Program (Barrett, Fry, Maller, & Daly, 2005) was used to determine tagging SNPs based on HapMap data to obtain a proper coverage of the GDNF gene. In case of a number of options for tagging SNPs, a reference from previous association studies concerning neuropsychiatric disorders was preferred. We selected the following GDNF SNPs: rs3812047, rs11111, rs3096140, rs1549250, and rs2973033.

Table 1 presents the studied SNPs from the 3' UTR region of additional candidate genes implicated in addiction and other psychiatric disorders. SNPs selection was preceded by *in silico* searches using several miRNA databases to identify SNPs predicted to alter miRNA binding within the 3' UTR, therefore, more likely to be a risk factor for the phenotype.

Sample preparation and SNP genotyping

Collection of samples and isolation of genomic DNA from buccal swabs were carried out as described previously (Boor et al., 2002). Concentration of the extracted DNA was measured using NanoDropTM 1000 (Thermo Fisher Scientific, Waltham, MA, USA).

Genotyping procedure

Genotyping of the GDNF gene (real-time PCR). Genotyping was carried out on the real-time cycler ABI Prism 7300 Real-Time PCR System (Thermo Fisher Scientific). Five SNPs of the GDNF gene located in chromosome position 5p12–p13.1 were genotyped using pre-designed TaqMan® kits with FAM and VIC fluorescent probes: rs3812047 (C_27492935_10), rs11111 (C_8813050_1_), rs1549250 (C_11553504_10), rs3096140 (C_1395038_20), and rs2973033 (C_15958567_10).

Table 1. SNPs investigated with the OpenArray genotyping system

Gene	Gene name	SNP			
AADAC	Arylacetamide deacetylase	rs1042201			
ACP1	Acid phosphatase 1, soluble	rs6855			
CNR1	Cannabinoid receptor 1	rs4707436			
		rs806368			
CNTNAP2	Contactin-associated protein-like 2	rs1062072			
		rs2530310			
		rs2530311			
		rs987456			
COMT	Catechol-O-methyltransferase	rs165599			
		rs165728			
DRD2	Dopamine receptor D2	rs6276			
		rs6278			
GDNF	Glial cell-derived neurotrophic	rs2973051			
	factor	rs3749692			
		rs62360370			
HTR2A	5-Hydroxytryptamine receptor 2A	rs3125			
IL1RN	Interleukin 1 receptor antagonist	rs4252041			
IMMP2L					
	peptidase subunit 2	rs17158195			
		rs7795011			
LHX6	LIM homeobox 6	rs3750486			
		rs74370188			
MAOA	monoamine oxidase A	rs3027407			
MEIS1	Meis homeobox 1	rs72824830			
MIR302A		rs114318553			
NTN4	Netrin 4	rs1052651			
		rs8699			
SLC6A3	Solute carrier family 6 member 3	rs11564774			
		rs7732456			
SLITRK1	SLIT- and NTRK-like family	rs3737193			
	member 1	rs41557622			
TNF	Tumor necrosis factor	rs3093665			

Note. SNP: single nucleotide polymorphism.

OpenArray SNPs genotyping. Genotyping of SNPs mentioned in Table 1 was performed on a TaqMan® OpenArray® Genotyping System (Thermo Fisher Scientific). The processing of raw data was performed using TaqMan® Genotyping Software (Thermo Fisher Scientific). We regenotyped 10% of samples as a quality control step to avoid any batch effects. Out of the 32 SNPs considered for assessment, 27 SNPs were successfully genotyped. Out of the 5 SNPs not included in the statistical analysis, three were non-successfully genotyped (rs41557622 of SLITRK1; rs1062072 and rs2530310 of CNTNAP2) and two were found to be non-polymorphic (rs72824830 of MEIS1 and rs4252041 of IL1R).

Statistical analyses

Standard case—control association analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). The p values <.05 were considered nominally significant. Correction for multiple testing was made according to the Bonferroni method: the threshold significance was adjusted to p <.0015625 where .0015625 = .05/32 (since 5 + 27 = 32 SNPs, genotyped by the two different methods, were used for the final statistical analysis). We applied the

most stringent Bonferroni correction for multiple testing to rule out type I errors in null hypothesis testing. In order to estimate the statistical power of our pilot sample, we performed a post-hoc power calculation using the G*Power software (Faul, Erdfelder, Lang, & Buchner, 2007) to determine the necessary sample size to find significant genetic effects. With a 0.1 effect size (partial eta square value by two groups), by a power set to be at least 0.80, it was determined that 964 participants would be needed in the total sample to detect such an association.

Ethics

The study protocol was approved by the Departmental Research Committee (DRC) of the School of Human Sciences, North Eastern Hill University. Written informed consent was obtained from all participating individuals.

RESULTS

Real-time PCR genotyping results

MAFs of the GDNF SNPs in this study were compared to other Asian population from the HapMap Project (http://www.ncbi.nlm.nih.gov). No significant deviation was observed from the MAFs of Asian population.

A case–control study was conducted to explore possible association of various GDNF gene SNPs with gambling (Table 2). Table 3 shows the results of χ^2 tests of genotype distribution differences between cases and controls, numbers, and percentages of individuals in each genotype group for (a) non-gamblers (control individuals with no history of gambling) and (b) gamblers. We observed nominally significant differences in case of rs2973033 (p = .00027, $\chi^2 = 16.391$, df = 2), rs3812047 (p = .00314, $\chi^2 = 8.719$, df = 1) and rs1549250 (p = .045, $\chi^2 = 6.191$, df = 2). After correcting for multiple testing, only rs2973033 remained significant (corrected p = .00864).

In case of GDNF SNP rs1549250, the AA and CC genotypes showed higher frequency in case of the non-gamblers (18% and 51%, respectively) compared to those who gambled (13.7% and 37.9%, respectively). In contrast, the frequency of heterozygote AC was higher in individuals who gambled (48.4%) compared to those who never gambled (31%). In case of GDNF SNP rs3812047, the frequency of the CT genotype was higher in gamblers

Table 2. Location of the real-time PCR-analyzed genetic variants in the vicinity of the GDNF gene

SNP	Location within the gene
rs2973033	5′ UTR
rs3096140	Intron
rs3812047	Intron
rs1549250	Intron
rs11111	3' UTR

Note. SNP: single nucleotide polymorphism; PCR: polymerase chain reaction; GDNF: glial cell line-derived neurotrophic factor; UTR: untranslated region.

Table 3. The case-control analysis of any form of gambling and GDNF SNPs

	Genotype	Non-gamblers		Gamblers				
GDNF SNP		N	%	\overline{N}	%	p	Corrected p value	χ^2
rs2973033	CC	40	40	13	14	.00027**	.00864	16.391
	TT	16	16	22	23.7			
	CT	44	44	58	62.4			
	Total	100		93				
rs3096140	AA	52	60.5	51	56.7	.444	1	1.623
	GG	9	10.5	6	6.7			
	AG	25	29.1	33	36.7			
	Total	86		90				
rs3812047	CC	94	94	75	79.8	.00314*	.10048	8.719
	TT	_	_	_	_			
	CT	6	6	19	20.2			
	Total	100		94				
rs1549250	AA	18	18	13	13.7	.045*	1	6.191
	CC	51	51	36	37.9			
	AC	31	31	46	48.4			
	Total	100		95				
rs11111	CC	8	8.1	4	4.2	.286	1	2.504
	TT	66	66.7	59	62.1			
	CT	25	25.3	32	33.7			
	Total	99		95				

Note. χ^2 : chi-square value; p: p value with .05 significance level; SNP: single nucleotide polymorphism; GDNF: glial cell line-derived neurotrophic factor.

(20.2%) than non-gamblers (6%), suggesting a protective role for the more common CC genotype (the TT homozygous genotype was absent from both groups in our sample). Nevertheless, the above results did not survive Bonferroni correction for multiple testing.

When looking at rs2973033, we observed that the frequency of CT and TT genotypes is higher in case of gamblers (62.4% and 23.7%, respectively) compared to non-gamblers (44% and 16%, respectively). The result suggests that the CT and TT genotypes might serve as risk factors, whereas the CC genotype could be protective against gambling (p = .00027, $\chi^2 = 16.391$, df = 2). The association of rs2979033 with gambling remained statistically significant after Bonferroni correction for multiple testing (corrected p = .00864).

OpenArray genotyping results

Table 4 shows the top hits (p < .05) of the case–control analysis involving the 3' UTR SNPs genotyped on the OpenArray platform; detailed results of the successfully genotyped SNPs are available in Supplementary Table S1. SNP rs74370188 in the LHX6 gene showed a nominally significant $(p = .01571, \chi^2 = 5.834, df = 1)$ association in the χ^2 test. The frequency of the most prevalent GG genotype is higher in non-gamblers (78.0%) than in gamblers (61.7%). However, rs74370188 does not survive the Bonferroni correction for multiple testing.

In the case of rs2530311 located in CNTNAP2 gene, we observed a significant association (p = .00140, $\chi^2 = 13.132$, df = 2) in the χ^2 test, which withstands correction for

Table 4. The top two SNPs (p < .05) of the case–control analysis of any form of gambling and SNPs in 3' UTR: OpenArray results

		Non-g	Non-gamblers		nblers				
	Genotype	N	%	\overline{N}	%	p	Corrected p value	χ^2	OR
CNTNAP2									
rs2530311	AA	21	23.9	41	47.7	.00140**	.0448	13.132	NA
	GG	19	21.6	7	8.1				
	AG	48	54.5	38	44.2				
	Total	88		86					
LHX6									
rs74370188	AA	_	_	_	_	.01571*	.5072	5.834	0.454
	GG	71	78	58	61.7				
	AG	20	22	36	38.3				
	Total	91		94					

Note. χ^2 : Chi-square value; OR: odds ratio; UTR: untranslated region; SNP: single nucleotide polymorphism; NA: not applicable; p: p value with .05 significance level.

^{*}Nominally significant (p < .05). **Significant after multiple correction (p < .001).

^{*}Nominally significant (p < .05). **Significant after multiple correction (p < .001).

multiple testing (corrected p = .0448). The frequency of the AA genotype of rs2530311 is higher in case of gamblers (47.7%) compared to non-gamblers (23.9%). Thus, the AA genotype seems to be the risk factor for gambling.

DISCUSSION

This study was conducted on a population of gamblers involved in a local archery game in Meghalaya, India. The traditional sport, commonly known as "teer," has gained widespread popularity among locals of Shillong in part due to the high odds offered by the organizers, allowing winners to take home 80 times the sum that was gambled.

Our case–control genetic analysis identified two significant associations between gambling and the GDNF gene SNP rs2973033 (p = .00864, $\chi^2 = 16.391$, df = 2) and the CNTNAP2 gene SNP rs2530311 (p = .0448, $\chi^2 = 13.132$, df = 2) after correction for multiple testing.

GDNF is a well-studied gene associated with addiction and plays a role in several processes including drug reward, drug self-administration, relapse, and abstinence (Ghitza et al., 2010; Wise, 2004). The gene encodes a secreted ligand of the transforming growth factor-beta (TGF-β) receptor superfamily of proteins. Upon ligand binding to various TGF-β receptors, transcription factors of the SMAD family are recruited and activated, resulting in gene expression changes. GDNF is involved in the growth, survival, and morphological differentiation of dopaminergic neurons during development as well as enhanced high-affinity uptake of dopamine in rat embryonic midbrain cells (Lin, Doherty, Lile, Bektesh, & Collins, 1993). The role of GDNF in reward mechanisms has been shown in animal model studies with drugs like cocaine, methamphetamine, and alcohol (Ghitza et al., 2010). Moreover, external injection of GDNF in rats was shown to reduce the impact of dopamine depletion observed during drug abstinence (Barak, Carnicella, Yowell, & Ron, 2011). A GDNF knockout study in mice has also shown increased sensitivity for alcohol in case of heterozygotes compared to wild-type homozygotes, thus confirming the role of endogenous GDNF in reducing the rewarding effects of ethanol (Carnicella, Ahmadiantehrani, Janak, & Ron, 2009). In a previous study conducted by our group, strong association was observed between GDNF SNPs rs3812047 and rs11111 with nicotine and betel quid use (unpublished data).

In this study, we report a significant association of rs2973033 in GDNF with game-based gambling. Our results confirm the role of GDNF in addiction, and to our knowledge, this is the first study to show association of GDNF gene polymorphisms with gambling as a type of behavioral addiction.

The CNTNAP2 gene codes for a neuronal transmembrane protein belonging to the neurexin superfamily involved in communication between neuronal cells (Condro & White, 2014). This protein is also involved in localization of potassium channels within differentiating axons (Poliak et al., 1999). The gene encompasses almost 1.5% of chromosome 7 and is one of the largest genes in the human genome. Due to its large extent, it is likely a target for structural rearrangements, including copy number

variations, translocations, altered transcription factor binding, and also epigenetic modifications, including miRNA regulation. The CNTNAP2 gene has been implicated in several neurodevelopmental disorders. Due to a translocation affecting the coding region of the gene, it was found to be associated with Gilles de la Tourette syndrome, intellectual disability, and obsessive-compulsive disorder (Verkerk et al., 2003). Other cognitive disorders, such as schizophrenia, epilepsy, autism, and attention-deficit hyperactivity disorder, were also linked to disruptions in CNTNAP2 gene (Rodenas-Cuadrado, Ho, & Vernes, 2014). SNP variants of this gene were also linked to various complex neurological disorders including autism (Alarcon et al., 2008; Arking et al., 2008; Strauss et al., 2006), schizophrenia, and depression (Ji et al., 2013). CNTNAP2 gene was previously identified in alcohol addiction (Song & Zhang, 2014). The study used a new computational method, tree-based analysis of rare variants, to investigate the effect of rare variants in complex disorders. The authors suggested that 97 rare variants of the CNTNAP2 gene could be protective against alcohol addiction in women. In this study, we found that the common variant rs2530311 of the CNTNAP2 gene is associated with gambling, thus corroborating the involvement of this gene in the addiction behavior.

The main limitation of the study is the relatively small sample size. However, this is a pilot study performed with a very unique, culturally distinct phenotype and even this collection has proven to be a great challenge. Thus, our final sample consisted of 196 participants, on which the exploratory genetic association analysis was conducted.

In conclusion, to our knowledge, this is the first study reporting a direct link between CNTNAP2 and game-based gambling. This study further confirms the role of GDNF in addiction, while it is the first study to show the association of GDNF polymorphism with gambling as a type of behavioral addiction.

Funding sources: AD was supported by Hungarian Scholarship Board Indian-Hungarian collaboration Scheme B Postgraduate program, 2014-2015: "Study on the genetic variants in gambling." LP was financed by FP7-People-2012-ITN, project: TS-Eurotrain, grant number 316978. CB was supported by funding from the Merit-prize fellowship of Semmelweis University, the Bolyai János research fellowship of the Hungarian Academy of Sciences BO/00987/ 16/5; the ÚNKP-18-4 of the new National Excellence Program of the Ministry of Human Capacities; and the Baron Munchausen Program of the Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University. The study was also supported by the Hungarian National Research, Development and Innovation Office (grant numbers: K111938 and KKP126835). The study was completed with the support of the Hungarian Ministry of Human Capacities (ELTE Institutional Excellence Program, 783-3/2018/FEKUTSRAT).

Authors' contribution: AD and BL collected the samples. AD, LP, AV, and CB performed the DNA extraction and genotyping. AD, LP, AV, and EK carried out the statistical analyses. All authors have contributed to the final

draft of the manuscript. AD and LP contributed equally to this work.

Conflict of interest: The authors declare no conflict of interest.

Acknowledgements: The authors would particularly like to thank all participants who took part in this study. They would also like to thank Ms. Cynthia Hunn for her kind assistance in editing the manuscript.

REFERENCES

- Abelson, J. F., Kwan, K. Y., O'Roak, B. J., Baek, D. Y., Stillman,
 A. A., Morgan, T. M., Mathews, C. A., Pauls, D. L., Rasin,
 M. R., Gunel, M., Davis, N. R., Ercan-Sencicek, A. G., Guez,
 D. H., Spertus, J. A., Leckman, J. F., Dure, L. S., Kurlan, R.,
 Singer, H. S., Gilbert, D. L., Farhi, A., Louvi, A., Lifton, R. P.,
 Sestan, N., & State, M. W. (2005). Sequence variants in
 SLITRK1 are associated with Tourette's syndrome. Science,
 310(5746), 317–320. doi:10.1126/science.1116502
- Alarcon, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., Sebat, J., Wigler, M., Martin, C. L., Ledbetter, D. H., Nelson, S. F., Cantor, R. M., & Geschwind, D. H. (2008). Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. *American Journal of Human Genetics*, 82(1), 150–159. doi:10.1016/j.ajhg.2007.09.005
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Washington, DC: American Psychiatric Association.
- Arking, D. E., Cutler, D. J., Brune, C. W., Teslovich, T. M., West, K., Ikeda, M., Rea, A., Guy, M., Lin, S., Cook, E. H., & Chakravarti, A. (2008). A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. *American Journal of Human Genetics*, 82(1), 160–164. doi:10.1016/j.ajhg.2007.09.015
- Bali, P., & Kenny, P. J. (2013). MicroRNAs and drug addiction. Frontiers in Genetics, 4, 43. doi:10.3389/fgene.2013.00043
- Barak, S., Carnicella, S., Yowell, Q. V., & Ron, D. (2011). Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: Implications for alcohol reward and seeking. *Journal of Neuroscience*, 31(27), 9885–9894. doi:10.1523/JNEUROSCI.1750-11.2011
- Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. *Bioinformatics*, 21(2), 263–265. doi:10.1093/bioinformatics/bth457
- Bertelsen, B., Stefansson, H., Jensen, L. R., Melchior, L., Debes, N. M., Groth, C., Skov, L., Werge, T., Karagiannidis, I., Tarnok, Z., & Barta, C. (2016). Association of AADAC deletion and Gilles de la Tourette Syndrome in a large European cohort. *Biological Psychiatry*, 79(5), 383–391. doi:10.1016/j.biopsych.2015.08.027
- Beveridge, N. J., Gardiner, E., Carroll, A. P., Tooney, P. A., & Cairns, M. J. (2010). Schizophrenia is associated with an increase in cortical microRNA biogenesis. *Molecular Psychiatry*, 15(12), 1176–1189. doi:10.1038/mp.2009.84
- Boor, K., Ronai, Z., Nemoda, Z., Gaszner, P., Sasvari-Szekely, M., Guttman, A., & Kalasz, H. (2002). Noninvasive genotyping of

- dopamine receptor D4 (DRD4) using nanograms of DNA from substance-dependent patients. *Current Medicinal Chemistry*, *9*(8), 793–797. doi:10.2174/0929867024606821
- Cao, J., Liu, X. T., Han, S. Z., Zhang, C. K., Liu, Z. Z., & Li, D. W. (2014). Association of the HTR2A gene with alcohol and heroin abuse. *Human Genetics*, 133(3), 357–365. doi:10.1007/ s00439-013-1388-y
- Carnicella, S., Ahmadiantehrani, S., Janak, P. H., & Ron, D. (2009). GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence. *Alcoholism-Clinical and Experimental Research*, 33(6), 1012–1024. doi:10.1111/j.1530-0277.2009. 00922.x
- Clarke, T. K., Bloch, P. J., Ambrose-Lanci, L. M., Ferraro, T. N., Berrettini, W. H., Kampman, K. M., Dackis, C. A., Pettinati, H. M., O'Brien, C. P., Oslin, D. W., & Lohoff, F. W. (2013). Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: Confirmation in an independent sample and meta-analysis. *Addiction Biology*, 18(4), 702–708. doi:10.1111/j.1369-1600.2011.00346.x
- Condro, M. C., & White, S. A. (2014). Distribution of languagerelated Cntnap2 protein in neural circuits critical for vocal learning. *The Journal of Comparative Neurology*, 522(1), 169–185. doi:10.1002/cne.23394
- Fagundo, A. B., Fernandez-Aranda, F., de la Torre, R., Verdejo-Garcia, A., Granero, R., Penelo, E., Gené, M., Barrot, C., Sánchez, C., Alvarez-Moya, E., & Ochoa, C. (2014). Dopamine DRD2/ANKK1 Taq1A and DAT1 VNTR polymorphisms are associated with a cognitive flexibility profile in pathological gamblers. *Journal of Psychopharmacology*, 28(12), 1170–1177. doi:10.1177/0269881114551079
- Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39(2), 175–191. doi:10.3758/BF03193146
- Ghitza, U. E., Zhai, H. F., Wu, P., Airavaara, M., Shaham, Y., & Lu, L. (2010). Role of BDNF and GDNF in drug reward and relapse: A review. *Neuroscience and Biobehavioral Reviews*, 35(2), 157–171. doi:10.1016/j.neubiorev.2009.11.009
- Grant, J. E., Leppink, E. W., Redden, S. A., Odlaug, B. L., & Chamberlain, S. R. (2015). COMT genotype, gambling activity, and cognition. *Journal of Psychiatric Research*, 68, 371–376. doi:10.1016/j.jpsychires.2015.04.029
- Grant, J. E., Potenza, M. N., Weinstein, A., & Gorelick, D. A. (2010). Introduction to behavioral addictions. *American Journal of Drug and Alcohol Abuse*, 36(5), 233–241. doi:10.3109/00952990.2010.491884
- Guillot, C. R., Fanning, J. R., Liang, T. B., & Berman, M. E. (2015). COMT associations with disordered gambling and drinking measures. *Journal of Gambling Studies*, 31(2), 513–524. doi:10.1007/s10899-013-9434-1
- Gyollai, A., Griffiths, M. D., Barta, C., Vereczkei, A., Urban, R., Kun, B., Kokonyei, G., Székely, A., Sasvári-Székely, M., Blum, K., & Demetrovics, Z. (2014). The genetics of problem and pathological gambling: A systematic review. *Current Pharmaceutical Design*, 20(25), 3993–3999. doi:10.2174/ 13816128113199990626
- Hammerschlag, A. R., Stringer, S., de Leeuw, C. A., Sniekers, S., Taskesen, E., Watanabe, K., Blanken, T. F., Dekker, K., Te Lindert, B. H., Wassing, R., & Jonsdottir, I. (2017). Genomewide association analysis of insomnia complaints identifies risk

- genes and genetic overlap with psychiatric and metabolic traits. *Nature Genetics*, 49(11), 1584–1592. doi:10.1038/ng.3888
- Heberlein, A., Kaser, M., Lichtinghagen, R., Rhein, M., Lenz, B., Kornhuber, J., Bleich, S., & Hillemacher, T. (2014). TNF-alpha and IL-6 serum levels: Neurobiological markers of alcohol consumption in alcohol-dependent patients? *Alcohol*, 48(7), 671–676. doi:10.1016/j.alcohol.2014.08.003
- Hillemacher, T., Bleich, S., Frieling, H., Buchholz, V., Hussein, R., Meyer, C., Meyer, C., John, U., Bischof, A., & Rumpf, H. J. (2016). Dopamine-receptor 2 gene-methylation and gambling behavior in relation to impulsivity. *Psychiatry Research*, 239, 154–155. doi:10.1016/j.psychres.2016.03.021
- Ibanez, A., Perez de Castro, I., Fernandez-Piqueras, J., Blanco, C., & Saiz-Ruiz, J. (2000). Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. *Molecular Psychiatry*, 5(1), 105–109. doi:10.1038/sj.mp.4000654
- Icick, R., Peoc'h, K., Karsinti, E., Ksouda, K., Hajj, A., Bloch, V., Prince, N., Mouly, S., Bellivier, F., Lépine, J. P., & Laplanche, J. L. (2015). A Cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients. *American Journal on Addictions*, 24(7), 613–620. doi:10.1111/ajad.12273
- Ji, W., Li, T., Pan, Y., Tao, H., Ju, K., Wen, Z., Fu, Y., An, Z., Zhao, Q., Wang, T., & He, L. (2013). CNTNAP2 is significantly associated with schizophrenia and major depression in the Han Chinese population. *Psychiatry Research*, 207(3), 225–228. doi:10.1016/j.psychres.2012.09.024
- Joutsa, J., Hirvonen, M. M., Arponen, E., Hietala, J., & Kaasinen, V. (2014). DRD2-related TaqIA genotype is associated with dopamine release during a gambling task. *Journal of Addiction Medicine*, 8(4), 294–295. doi:10.1097/ADM.00000000000 00037
- Kapelski, P., Skibinska, M., Maciukiewicz, M., Pawlak, J., Dmitrzak-Weglarz, M., Szczepankiewicz, A., Zaremba, D., & Twarowska-Hauser, J. (2016). An association between functional polymorphisms of the interleukin 1 gene complex and schizophrenia using transmission disequilibrium test. Archivum Immunologiae et Therapiae Experimentalis, 64(Suppl. 1), 161–168. doi:10.1007/s00005-016-0434-6
- Kordi-Tamandani, D. M., Tajoddini, S., & Salimi, F. (2015). Promoter methylation and BDNF and DAT1 gene expression profiles in patients with drug addiction. *Pathobiology*, 82(2), 94–99. doi:10.1159/000430465
- Kotyuk, E., Nemeth, N., Ronai, Z., Demetrovics, Z., Sasvari-Szekely, M., & Szekely, A. (2016). Association between smoking behaviour and genetic variants of glial cell line-derived neurotrophic factor. *Journal of Genetics*, 95(4), 811–818. doi:10.1007/s12041-016-0701-7
- Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., & Collins, F. (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science*, 260(5111), 1130–1132. doi:10.1126/science.8493557
- Paschou, P., Stylianopoulou, E., Karagiannidis, I., Rizzo, R., Tarnok, Z., Wolanczyk, T., Hebebrand, J., Nöthen, M. M., Lehmkuhl, G., Farkas, L., & Nagy, P. (2012). Evaluation of the LIM homeobox genes LHX6 and LHX8 as candidates for Tourette syndrome. *Genes, Brain, and Behavior, 11*(4), 444–451. doi:10.1111/j.1601-183X.2012.00778.x
- Paschou, P., Yu, D., Gerber, G., Evans, P., Tsetsos, F., Davis, L. K., Karagiannidis, I., Chaponis, J., Gamazon, E., Mueller-Vahl, K., & Stuhrmann, M. (2014). Genetic

- association signal near NTN4 in Tourette syndrome. *Annals of Neurology*, 76(2), 310–315. doi:10.1002/ana.24215
- Perez-Rubio, G., Ramirez-Venegas, A., Diaz, V. N., Gomez, L. G., Fabian, K. E., Carmona, S. G., López-Flores, L. A., Ambrocio-Ortiz, E., Romero, R. C., Alcantar-Ayala, N., & Sansores, R. H. (2017). Polymorphisms in HTR2A and DRD4 predispose to smoking and smoking quantity. *PLoS One*, 12(1), e0170019. doi:10.1371/journal.pone.0170019
- Petek, E., Windpassinger, C., Vincent, J. B., Cheung, J., Boright, A. P., Scherer, S. W., Kroisel, P. M., & Wagner, K. (2001). Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. *American Journal of Human Genetics*, 68(4), 848–858. doi:10.1086/319523
- Poliak, S., Gollan, L., Martinez, R., Custer, A., Einheber, S., Salzer, J. L., Trimmer, J. S., Shrager, P., & Peles, E. (1999). Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. *Neuron*, 24(4), 1037–1047. doi:10.1016/S0896-6273(00)81049-1
- Robbins, T. W., & Clark, L. (2015). Behavioral addictions. Current Opinion in Neurobiology, 30, 66–72. doi:10.1016/j.conb.2014.09.005
- Rodenas-Cuadrado, P., Ho, J., & Vernes, S. C. (2014). Shining a light on CNTNAP2: Complex functions to complex disorders. *European Journal of Human Genetics*, 22(2), 171–178. doi:10.1038/ejhg.2013.100
- Ron, D., & Janak, P. H. (2005). GDNF and addiction. *Reviews in the Neurosciences*, *16*(4), 277–285. doi:10.1515/REVNEURO.2005.16.4.277
- Shaffer, H. J., Hall, M. N., & Vander Bilt, J. (1999). Estimating the prevalence of disordered gambling behavior in the United States and Canada: A research synthesis. *American Journal* of *Public Health*, 89(9), 1369–1376. doi:10.2105/AJPH. 89.9.1369
- Sim, M. S., Soga, T., Pandy, V., Wu, Y. S., Parhar, I. S., & Mohamed, Z. (2017). MicroRNA expression signature of methamphetamine use and addiction in the rat nucleus accumbens. *Metabolic Brain Disease*, *32*(6), 1767–1783. doi:10.1007/s11011-017-0061-x
- Smith, A. C. W., & Kenny, P. J. (2017). MicroRNAs regulate synaptic plasticity underlying drug addiction. *Genes, Brain, and Behavior, 17*(3), e12424. doi:10.1111/gbb.12424
- Song, C., & Zhang, H. P. (2014). TARV: Tree-based analysis of rare variants identifying risk modifying variants in CTNNA2 and CNTNAP2 for alcohol addiction. *Genetic Epidemiology*, 38(6), 552–559. doi:10.1002/gepi.21843
- Speed, W. C., O'Roak, B. J., Tarnok, Z., Barta, C., Pakstis, A. J., State, M. W., & Kidd, K. K. (2008). Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette syndrome. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics*, 147B(4), 463–466. doi:10.1002/ajmg.b.30641
- Stolf, A. R., Szobot, C. M., Halpern, R., Akutagava-Martins, G. C., Muller, D., Guimaraes, L. S. P., Kessler, F. H., Pechansky, F., & Roman, T. (2014). Crack cocaine users show differences in genotype frequencies of the 3' UTR variable number of tandem repeats of the dopamine transporter gene (DAT1/SLC6A3). Neuropsychobiology, 70(1), 44–51. doi:10.1159/000365992
- Strauss, K. A., Puffenberger, E. G., Huentelman, M. J., Gottlieb, S., Dobrin, S. E., Parod, J. M., Stephan, D. A., & Morton, D. H. (2006). Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. *The New*

- England Journal of Medicine, 354(13), 1370–1377. doi:10.1056/NEJMoa052773
- Verdejo-Garcia, A., Fagundo, A. B., Cuenca, A., Rodriguez, J., Cuyas, E., Langohr, K., de Sola Llopis, S., Civit, E., Farré, M., Peña-Casanova, J., & de la Torre, R. (2013). COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in Cannabis users. *Neuropsychopharmacology*, 38(8), 1598–1606. doi:10.1038/npp.2013.59
- Verkerk, A. J., Mathews, C. A., Joosse, M., Eussen, B. H., Heutink, P., Oostra, B. A., & Tourette Syndrome Association International Consortium for Genetics. (2003). CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. *Genomics*, 82(1), 1–9. doi:10.1016/S0888-7543(03)00097-1
- Welte, J. W., Barnes, G. M., Tidwell, M. C. O., Hoffman, J. H., & Wieczorek, W. F. (2015). Gambling and problem gambling in the United States: Changes between 1999 and 2013. *Journal of Gambling Studies*, 31(3), 695–715. doi:10.1007/s10899-014-9471-4
- Willour, V. L., Seifuddin, F., Mahon, P. B., Jancic, D., Pirooznia, M., Steele, J., Schweizer, B., Goes, F. S., Mondimore, F. M.,

- Mackinnon, D. F., Bipolar Genome Study Consortium, Perlis, R. H., Lee, P. H., Huang, J., Kelsoe, J. R., Shilling, P. D., Rietschel, M., Nöthen, M., Cichon, S., Gurling, H., Purcell, S., Smoller, J. W., Craddock, N., DePaulo, J. R., Jr., Schulze, T. G., McMahon, F. J., Zandi, P. P., & Potash, J. B. (2012). A genome-wide association study of attempted suicide. *Molecular Psychiatry*, 17(4), 433–444. doi:10.1038/mp.2011.4
- Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews Neuroscience, 5(6), 483–494. doi:10.1038/ nrn1406
- Xuan, Y. H., Li, S., Tao, R., Chen, J., Rao, L. L., Wang, X. T., & Zheng, R. (2017). Genetic and environmental influences on gambling: A meta-analysis of twin studies. *Frontiers in Psychology*, 8, 2121. doi:10.3389/fpsyg.2017.02121
- Yoshimura, T., Usui, H., Takahashi, N., Yoshimi, A., Saito, S., Aleksic, B., Ujike, H., Inada, T., Yamada, M., Uchimura, N., Iwata, N., Sora, I., Iyo, M., & Ozaki, N. (2011). Association analysis of the GDNF gene with methamphetamine use disorder in a Japanese population. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 35(5), 1268–1272. doi:10.1016/j.pnpbp.2011.04.003